CN Mobile Logo

Search form


Palliative Rx for prostate ca wins OK from FDA

Palliative Rx for prostate ca wins OK from FDA

Trelstar (22.5 mg triptorelin pamoate) has received FDA marketing approval as a twice-yearly intramuscular gonadotropin-releasing hormone (GnRH) agonist. Trelstar suppresses testosterone production for six months, according to manufacturer Watson Pharmaceuticals. Approval was based on a 12-month, phase III efficacy and safety study of Trelstar given every six months in patients with advanced disease. Trelstar produced a mean testosterone serum level of 12.8 ng/dL from month two through month 12, which was well below castration levels associated with androgen deprivation therapy, according to Watson.

By day 29, 97.5% of the clinical trial patients achieved castrate level, and more than 98% of all patients were below castrate level at month six and month 12. Median prostate-specific antigen (PSA) was also reduced by 96.4% at the end of the study. The most commonly reported adverse event was hot flushes (71.7%).

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.